New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Mark Cuban: A Master Disrupter for American Health...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
High-speed imaging tracks live brain cell activity...
World is falling behind on UN's child mortality Sustainable ...
April 16,2026
Health literacy initiative improves discharge education, rea...
April 15,2026
Constipation is common, but with simple changes, you can man...
April 14,2026
Children and teenagers more open to meat free diets—but stru...
April 13,2026
3D-printed ATLAS platform helps model cancer cell clusters b...
April 12,2026
3 million-cell map shows menopause reshapes breast tissue, p...
April 11,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Los 20 tipos de cáncer más comunes: causas, síntomas y tratamiento

Los 20 tipos de cáncer más comunes: causas, síntomas y tratamiento

Los 20 tipos de cáncer más comunes: causas, síntomas y tratamientoRepasamos cuáles son los subtipos de esta enfermedad que afectan a más gente a nivel mundial.Pol Bertran PrietoMicrobiólogo, divulgado
World medicine November 28,2023
Los 20 tipos de cáncer más comunes: causas, síntomas y tratamiento

Los 20 tipos de cáncer más comunes: causas, síntomas y tratamiento

Los 20 tipos de cáncer más comunes: causas, síntomas y tratamientoRepasamos cuáles son los subtipos de esta enfermedad que afectan a más gente a nivel mundial.Pol Bertran PrietoMicrobiólogo, divulgado
World medicine November 28,2023
Today's News
Why is Alzheimer’s disease so difficult to treat? ...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
New multimodal signature could predict immunotherapy success

New multimodal signature could predict immunotherapy success

byUniversity of InnsbruckCredit:iScience(2024). DOI: 10.1016/j.isci.2024.110529An international team of researchers led by Francesca Finotello from the Digital Science Center (DiSC)
Oncology September 27,2024
New multimodal signature could predict immunotherapy success

New multimodal signature could predict immunotherapy success

byUniversity of InnsbruckCredit:iScience(2024). DOI: 10.1016/j.isci.2024.110529An international team of researchers led by Francesca Finotello from the Digital Science Center (DiSC)
Oncology September 27,2024
Double trouble for triple-negative breast cancer: Two-pronged strategy restores immunotherapy sensitivity

Double trouble for triple-negative breast cancer: Two-pronged strategy restores immunotherapy sensitivity

by Kimberly McGhee,Medical University of South CarolinaTumor-fighting immune cells in the tumor before (left) and after (right) combination therapy. After combination therapy, many more tumor-fi
Oncology September 27,2024
Double trouble for triple-negative breast cancer: Two-pronged strategy restores immunotherapy sensitivity

Double trouble for triple-negative breast cancer: Two-pronged strategy restores immunotherapy sensitivity

by Kimberly McGhee,Medical University of South CarolinaTumor-fighting immune cells in the tumor before (left) and after (right) combination therapy. After combination therapy, many more tumor-fi
Oncology September 27,2024
Trial demonstrates firmonertinib is a potential therapy for patients with NSCLC with EGFR PACC mutations

Trial demonstrates firmonertinib is a potential therapy for patients with NSCLC with EGFR PACC mutations

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe tyrosine kinase inhibitor firmonertinib showed promising efficacy in patients with non-small cell lung can
Oncology September 27,2024
Trial demonstrates firmonertinib is a potential therapy for patients with NSCLC with EGFR PACC mutations

Trial demonstrates firmonertinib is a potential therapy for patients with NSCLC with EGFR PACC mutations

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe tyrosine kinase inhibitor firmonertinib showed promising efficacy in patients with non-small cell lung can
Oncology September 27,2024
Aumolertinib shows improved progression-free survival in stage III non-small cell lung cancer

Aumolertinib shows improved progression-free survival in stage III non-small cell lung cancer

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe epidermal growth factor receptor tyrosine kinase inhibitor aumolertinib demonstrated improved progression-
Oncology September 27,2024
Aumolertinib shows improved progression-free survival in stage III non-small cell lung cancer

Aumolertinib shows improved progression-free survival in stage III non-small cell lung cancer

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe epidermal growth factor receptor tyrosine kinase inhibitor aumolertinib demonstrated improved progression-
Oncology September 27,2024
Elle Macpherson says she refused chemotherapy after breast cancer diagnosis—here's what oncologists think

Elle Macpherson says she refused chemotherapy after breast cancer diagnosis—here's what oncologists think

byUniversity of VirginiaCredit: Pixabay/CC0 Public DomainAfter being diagnosed with breast cancer seven years ago, Elle Macpherson made a controversial choice: She refused chemotherapy, the mode
Oncology September 27,2024
Elle Macpherson says she refused chemotherapy after breast cancer diagnosis—here's what oncologists think

Elle Macpherson says she refused chemotherapy after breast cancer diagnosis—here's what oncologists think

byUniversity of VirginiaCredit: Pixabay/CC0 Public DomainAfter being diagnosed with breast cancer seven years ago, Elle Macpherson made a controversial choice: She refused chemotherapy, the mode
Oncology September 27,2024
Palliative low-dose radiotherapy improves pain in hepatic cancer

Palliative low-dose radiotherapy improves pain in hepatic cancer

by Elana GotkineFor adults with hepatocellular carcinoma or liver metastases, low-dose liver radiotherapy plus best supportive care improve pain compared with best supportive care alone, according to
Oncology September 27,2024
Palliative low-dose radiotherapy improves pain in hepatic cancer

Palliative low-dose radiotherapy improves pain in hepatic cancer

by Elana GotkineFor adults with hepatocellular carcinoma or liver metastases, low-dose liver radiotherapy plus best supportive care improve pain compared with best supportive care alone, according to
Oncology September 27,2024
Preclinical study finds novel bone cancer therapy has 99% success rate

Preclinical study finds novel bone cancer therapy has 99% success rate

byAston UniversityProfessor Richard Martin. Credit: Aston UniversityBioactive glasses, a filling material which can bond to tissue and improve the strength of bones and teeth, has been combined
Oncology September 27,2024
Preclinical study finds novel bone cancer therapy has 99% success rate

Preclinical study finds novel bone cancer therapy has 99% success rate

byAston UniversityProfessor Richard Martin. Credit: Aston UniversityBioactive glasses, a filling material which can bond to tissue and improve the strength of bones and teeth, has been combined
Oncology September 27,2024
Pollution exposure may affect lung cancer in women who have never smoked

Pollution exposure may affect lung cancer in women who have never smoked

by International Association for the Study of Lung CancerCredit: Unsplash/CC0 Public DomainRecent air pollution exposure in the form of particles smaller than 2.5 micrometers (PM2.5) exposure may sign
Oncology September 27,2024
Pollution exposure may affect lung cancer in women who have never smoked

Pollution exposure may affect lung cancer in women who have never smoked

by International Association for the Study of Lung CancerCredit: Unsplash/CC0 Public DomainRecent air pollution exposure in the form of particles smaller than 2.5 micrometers (PM2.5) exposure may sign
Oncology September 27,2024
BMI's relation to cancer therapy mortality risks not so straightforward, study finds

BMI's relation to cancer therapy mortality risks not so straightforward, study finds

byOsaka Metropolitan UniversityFor non-small cell lung cancer treatment, immunotherapy seems to pose less risk for persons under a certain BMI, while conventional chemotherapy appears optimal fo
Oncology September 27,2024
BMI's relation to cancer therapy mortality risks not so straightforward, study finds

BMI's relation to cancer therapy mortality risks not so straightforward, study finds

byOsaka Metropolitan UniversityFor non-small cell lung cancer treatment, immunotherapy seems to pose less risk for persons under a certain BMI, while conventional chemotherapy appears optimal fo
Oncology September 27,2024
AI tool reveals cardiac risk for patients undergoing cancer therapy

AI tool reveals cardiac risk for patients undergoing cancer therapy

byYale School of MedicineBaseline AI-ECG screening for LVSD and all-cause mortality risk. Adjusted cumulative hazard curves for all-cause mortality stratified by the AI-ECG LVSD probability. Cre
Cardiovascular Diseases September 27,2024
AI tool reveals cardiac risk for patients undergoing cancer therapy

AI tool reveals cardiac risk for patients undergoing cancer therapy

byYale School of MedicineBaseline AI-ECG screening for LVSD and all-cause mortality risk. Adjusted cumulative hazard curves for all-cause mortality stratified by the AI-ECG LVSD probability. Cre
Cardiovascular Diseases September 27,2024
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu... ... Eye Infections (Updated) | Clinical Medicine ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com